PKC theta Antikörper (pThr538)
Kurzübersicht für PKC theta Antikörper (pThr538) (ABIN711746)
Target
Alle PKC theta (PRKCQ) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- pThr538
-
Kreuzreaktivität
- Human, Maus
-
Homologie
- Rat,Dog
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic phosphopeptide derived from human PRKCQ around the phosphorylation site of Thr538
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Haltbarkeit
- 12 months
-
-
-
Evidence of microglial activation following exposure to serum from first-onset drug-naïve schizophrenia patients." in: Brain, behavior, and immunity, Vol. 67, pp. 364-373, (2018) (PubMed).
: "
-
Evidence of microglial activation following exposure to serum from first-onset drug-naïve schizophrenia patients." in: Brain, behavior, and immunity, Vol. 67, pp. 364-373, (2018) (PubMed).
-
- PKC theta (PRKCQ) (Protein Kinase C, theta (PRKCQ))
-
Andere Bezeichnung
- PRKCQ
-
Hintergrund
-
Synonyms: PRKCT, nPKC-theta, Protein kinase C theta type, PRKCQ
Background: Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN, which in turn are essential for IL2 production, and participates to the calcium-dependent NFATC1 and NFATC2 transactivation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11 on several serine residues, inducing CARD11 association with lipid rafts and recruitment of the BCL10-MALT1 complex, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. May also play an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway leading to JUN activation, acts by phosphorylating the mediator STK39/SPAK and may not act through MAP kinases signaling. Plays a critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by participating in the regulation of reduced inositol 1,4,5-trisphosphate generation and intracellular calcium mobilization. After costimulation of T-cells through CD28 can phosphorylate CBLB and is required for the ubiquitination and subsequent degradation of CBLB, which is a prerequisite for the activation of TCR. During T-cells differentiation, plays an important role in the development of T-helper 2 (Th2) cells following immune and inflammatory responses, and, in the development of inflammatory autoimmune diseases, is necessary for the activation of IL17-producing Th17 cells. May play a minor role in Th1 response.
-
Gen-ID
- 5588
-
UniProt
- Q04759
-
Pathways
- T-Zell Rezeptor Signalweg, Fc-epsilon Rezeptor Signalübertragung, Myometrial Relaxation and Contraction, Regulation of G-Protein Coupled Receptor Protein Signaling, Thromboxane A2 Receptor Signaling
Target
-